Literature DB >> 11947918

Increased level of advanced oxidation protein products in patients with coronary artery disease.

Hideaki Kaneda1, Junichi Taguchi, Ken Ogasawara, Tadanori Aizawa, Minoru Ohno.   

Abstract

Witko-Sarsat et al. previously reported that advanced oxidation protein products (AOPP), which were determined by measurements of optical density (OD) at 340 nm under acidic conditions, were present at high levels in the plasma of uremic patients. We measured AOPP in the plasma of 392 patients who underwent coronary angiography because of suspected coronary artery disease (CAD) and examined the association between plasma AOPP levels and CAD. We also collected plasma from hemodialysis patients and healthy volunteers for AOPP assay. Plasma fractionation by size-exclusion chromatography was performed to determine the weights of the molecules involved in the AOPP activity. The elution patterns obtained after plasma fractionation by size-exclusion chromatography were the similar in both CAD and hemodialysis patients, but differed from those of the healthy volunteers, whose AOPP levels were low. We also found that, the severity score of CAD obtained by the Gensini scoring system had good correlation with AOPP quartiles. Multivariable regression models revealed that the plasma AOPP level was significantly related to CAD status. This is the first report of an association between AOPP and CAD. AOPP was an independent risk factor for CAD. Oxidative stress is speculated to be associated with the pathogenesis of CAD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11947918     DOI: 10.1016/s0021-9150(01)00706-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  30 in total

1.  Fructose-1,6-bisphosphate and N-acetylcysteine attenuate the formation of advanced oxidation protein products, a new class of inflammatory mediators, in vitro.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Lara Peruzzolo Cargnin; Manuela Borges Sangoi; Roberto Christ Vianna Santos; Patrícia Gomes; Rafael Noal Moresco
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Yi Feng; Chengxing Shen; Genshan Ma; Jihui Wang; Zhong Chen; Qiming Dai; Hong Zhi; Chengjian Yang; Qiang Fu; Gensheng Shang; Yuanyuan Guan
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

3.  Increased Advanced Oxidation Protein Products Generation by Cyclosporine-A and Angiotensin II in Human Gingival Fibroblasts - Ex-vivo Study.

Authors:  Suresh Ranga Rao; Rajasekaran Subbarayan; Supraja Ajitkumar; Dinesh Murugan Girija
Journal:  J Clin Diagn Res       Date:  2017-01-01

Review 4.  Immunomodulatory basis of antioxidant therapy and its future prospects: an appraisal.

Authors:  Y Ajith; U Dimri; S K Dixit; Shanker K Singh; A Gopalakrishnan; E Madhesh; J B Rajesh; S G Sangeetha
Journal:  Inflammopharmacology       Date:  2017-09-01       Impact factor: 4.473

5.  Increased Levels of Modified Advanced Oxidation Protein Products Are Associated with Central and Peripheral Blood Pressure in Peritoneal Dialysis Patients.

Authors:  Hong Xu; Ivan Cabezas-Rodriguez; Abdul Rashid Qureshi; Olof Heimburger; Peter Barany; Sunna Snaedal; Björn Anderstam; Ann-Christin Bragfors Helin; Juan Jesus Carrero; Peter Stenvinkel; Bengt Lindholm
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

6.  Increased myeloperoxidase activity and protein nitration are indicators of inflammation in patients with Chagas' disease.

Authors:  Monisha Dhiman; Jose Guillermo Estrada-Franco; Jasmine M Pando; Francisco J Ramirez-Aguilar; Heidi Spratt; Sara Vazquez-Corzo; Gladys Perez-Molina; Rosa Gallegos-Sandoval; Roberto Moreno; Nisha Jain Garg
Journal:  Clin Vaccine Immunol       Date:  2009-03-18

7.  Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling.

Authors:  Anthony J Valente; Tadashi Yoshida; Robert A Clark; Patrice Delafontaine; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Free Radic Biol Med       Date:  2013-02-20       Impact factor: 7.376

8.  Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population.

Authors:  Ufuk Cakatay; Refik Kayali; Hafize Uzun
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

9.  An alternative pathway through the Fenton reaction for the formation of advanced oxidation protein products, a new class of inflammatory mediators.

Authors:  Guilherme Vargas Bochi; Vanessa Dorneles Torbitz; Lara Peruzzolo Cargnin; José Antonio Mainardi de Carvalho; Patrícia Gomes; Rafael Noal Moresco
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

10.  CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction.

Authors:  Balachandar Venkatesan; Anthony J Valente; Nitin A Das; Andrea J Carpenter; Tadashi Yoshida; Jean-Luc Delafontaine; Ulrich Siebenlist; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2012-10-17       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.